Follicular activation in women previously diagnosed with poor ovarian response: a randomized, controlled trial.

Fecha de publicación: 01/04/2022 Fecha Ahead of Print: 01/03/2022

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

Simon C
Seli E

Grupos

Medicina Reproductiva

Investigador Principal

José Morales Roselló

Abstract

OBJECTIVE: To investigate whether ovarian fragmentation for follicular activation (OFFA) improves ovarian reserve markers and in vitro fertilization (IVF) outcomes in women with poor ovarian response (POR). DESIGN: Randomized, controlled trial, with parallel assignment. SETTING: University hospital. PATIENT(S): Thirty-four women with POR according to the European Society of Human Reproduction and Embryology criteria. INTERVENTION(S): Women with POR were randomly allocated to receive ovarian fragmentation in 1 ovary or to no intervention (control group). Ovarian reserve markers were followed at 2-week intervals for 6 months. In vitro fertilization cycles were initiated when the antral follicle count (AFC) doubled or at the end of follow-up. MAIN OUTCOME MEASURE(S): The primary outcome was the number of metaphase II (MII) oocytes obtained. Antral follicle count, antimüllerian hormone level, and reproductive outcomes were recorded as secondary outcomes. Exploratory outcomes included surgical results and analysis of protein and gene expression. RESULT(S): Ovarian fragmentation for follicular activation resulted in an increase in AFC in the intervention ovary compared with the control ovary and an increase in total AFC in the OFFA group compared with controls. Serum antimüllerian hormone and follicle-stimulating-hormone levels did not improve in the OFFA group throughout the follow-up period. Fifteen patients from each arm underwent IVF. In the control group, 33 MII oocytes were retrieved and 18 embryo transfers were performed, with a 20% pregnancy rate and an 18.7% live birth rate per cycle. In the OFFA group, 23 MII oocytes were retrieved and 11 embryo transfers were performed, with a 13.3% pregnancy rate and a 6.7% live birth rate per cycle. Reproductive outcomes did not significantly differ between the groups. Hippo pathway inhibition was confirmed by an 18.8% reduction in the phospho-YAP/YAP (Yes-associated protein 1) ratio and BIRC and CCN overexpression after fragmentation. CONCLUSION(S): Ovarian fragmentation for follicular activation in women with POR resulted in an increase in AFC but did not modify IVF outcomes when compared with controls. CLINICAL TRIAL REGISTRATION NUMBER: NCT02354963.

Datos de la publicación

ISSN/ISSNe:: 0015-0282, 1556-5653
Tipo:: Article
Páginas:: 747-755
DOI:: 10.1016/j.fertnstert.2021.12.034
Factor de Impacto:: 1,895 SCImago ℠
Cuartil:: Q1 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Díaz-García C:: Instituto Valenciano de Infertilidad-Reproductive Medicine Associates (IVIRMA) London, London, United Kingdom

Instituto Valenciano de Infertilidad (IVI) Foundation- Instituto de Investigaciones Sanitarias La Fe, Valencia, Spain

Elizabeth Garrett Anderson Institute for Women's Health (EGA IfWH), University College London (UCL), London, United Kingdom
Herraiz S:: Instituto Valenciano de Infertilidad (IVI) Foundation- Instituto de Investigaciones Sanitarias La Fe, Valencia, Spain
Pamplona L:: Fertility Preservation Unit, Women's Health Area, La Fe University Hospital, Valencia, Spain
Subirá J:: Fertility Preservation Unit, Women's Health Area, La Fe University Hospital, Valencia, Spain

Instituto Valenciano de Infertilidad-Reproductive Medicine Associates (IVIRMA) Valencia, Valencia, Spain
Soriano MJ:: Instituto Valenciano de Infertilidad (IVI) Foundation- Instituto de Investigaciones Sanitarias La Fe, Valencia, Spain

Fertility Preservation Unit, Women's Health Area, La Fe University Hospital, Valencia, Spain
Simon C:: Department of Obstetrics and Gynecology, Valencia University, Valencia, Spain

Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center (BIDMC) Harvard University, Boston, Massachusetts

Igenomix Foundation, Instituto de Investigación Sanitaria del Hospital Clínico de València (INCLIVA), Valencia, Spain
Seli E:: Instituto Valenciano de Infertilidad-Reproductive Medicine Associates (IVIRMA) New Jersey, Basking Ridge, New Jersey

Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, New Haven, Connecticut
Pellicer A:: Instituto Valenciano de Infertilidad (IVI) Foundation- Instituto de Investigaciones Sanitarias La Fe, Valencia, Spain

Department of Obstetrics and Gynecology, Valencia University, Valencia, Spain

Instituto Valenciano de Infertilidad-Reproductive Medicine Associates (IVIRMA) Rome, Rome, Italy